Aprogenex deal

The Houston company acquired from the Clayton Research Foundation, for 125,000 shares of common stock, U.S. Patent No. 5,225,326 covering one-step in situ hybridization, and three pending U.S. patent applications and their foreign counterparts. The company's core technology covered by the patent and pending patents had been exclusively licensed under a previous royalty agreement with Clayton. ...